Last updated: August 14, 2025
Introduction
UK patent GB2474930, granted on January 17, 2018, to Glaxo Group Limited, develops a novel approach for managing diseases involving the modulation of specific molecular pathways. This patent focus is on innovative pharmaceutical compositions and methods aimed at treating conditions such as inflammatory, autoimmune, or neoplastic disorders. A comprehensive understanding of its scope, claims, and the broader patent landscape provides strategic insight for stakeholders targeting therapeutic advancements.
Scope of Patent GB2474930
Technical Field and Background
GB2474930 centers on the design and use of pharmaceutical compounds that modulate receptor activity associated with disease pathogenesis. Its proprietary claims cover both the chemical entities involved and their application in specific therapeutic contexts. The patent emphasizes chemical structures capable of influencing immune responses, with particular relevance to cytokine modulation and receptor antagonism.
The background indicates a pressing need for improved treatments in immune regulation, especially in autoimmune diseases like rheumatoid arthritis and psoriasis. The patent aims to solve limitations associated with existing biologics and small-molecule therapies, such as adverse effects and limited bioavailability.
Core Innovation
The patent's core innovation lies in a class of small molecules characterized by specific chemical scaffolds capable of selectively inhibiting particular cytokine receptors or signaling pathways. These structures are designed to be orally bioavailable, stable, and efficacious, representing an advancement over previous biologic treatments that require parenteral administration.
Claims Analysis
The patent comprises 24 claims, segmented broadly into independent and dependent claims, defining the scope of protection.
Independent Claims
-
Claim 1: Describes a pharmaceutical composition comprising a specific chemical compound characterized by a core heterocyclic structure with particular substituents. It emphasizes the compound’s ability to inhibit cytokine receptor signaling pathways linked to immune and inflammatory responses.
-
Claim 2: Details a method of treating a disease associated with cytokine signaling by administering an effective amount of the compound of claim 1.
-
Claim 3: Specifies the use of the compound as a cytokine receptor antagonist.
Dependent Claims
Dependent claims specify particular substituents, polymorphs, formulations, or dosing regimens, such as:
-
Claims 4-10: Cover specific chemical variants, including different substituents on the heterocyclic core, synthesis methods, and pharmaceutical formulations like tablets or capsules.
-
Claims 11-15: Define dosage forms, IV or oral administration routes, and combination therapies with other known drugs.
-
Claims 16-24: Encompass methods of synthesis, different salt forms, and stability-inducing modifications to the core molecules.
Scope Implications
The claims primarily protect the chemical class of small molecules targeting cytokine pathways implicated in autoimmune and inflammatory diseases. The broad language in Claim 1 encompasses a range of compounds with similar scaffolds, providing a robust shield against infringing entities developing structurally similar molecules.
The method claims extend coverage from compounds themselves to their medical use, aligning with the "Swiss-type" claim format frequently employed in pharmaceutical patents.
Patent Landscape
Competitive Patent Parties
-
Primary Patent Holders: GlaxoSmithKline (GSK) holds GB2474930, reflecting its strategic investment in cytokine receptor modulators, likely targeting pathways such as IL-6, IL-17, or others central to immune regulation.
-
Related Patents and Applications: Several patents exist around cytokine receptor antagonists and small molecules, including international filings such as WO2017077642 (GSK), which describe similar chemical classes and therapeutic methods.
Key Patent Families
-
Chemical Class Patents: GSK holds multiple patent families covering heterocyclic compounds with various substitutions, intended for autoimmune and inflammatory disease treatment.
-
Method of Use Patents: These often overlap with chemical entities patents, aiming to secure exclusive rights over both composition and therapeutic applications.
-
Manufacturing and Formulation Patents: Additional IP covers specific synthesis methods and formulations, mitigating risk of generic competition.
Prosecution and Legal Status
-
Legal Status: GB2474930 is granted, conferring approximately 20 years of exclusivity beginning from the application date. No opposition or revocation proceedings are publicly documented.
-
Freedom to Operate (FTO): While GSK’s patent landscape appears comprehensive, potential overlaps with other cytokine receptor modulation patents necessitate careful FTO analyses, especially considering international filings.
Market and Innovation Trends
The patent landscape indicates a focus on small-molecule cytokine pathway inhibitors, competing with biologics and biosimilars. Key emerging players include other big pharma investors, like AbbVie and Novartis, pursuing similar targets to diversify autoimmune treatment options.
Implications for Industry and Research
-
Strategic Positioning: GB2474930 solidifies GSK’s stake in cytokine receptor modulation, especially for indications like rheumatoid arthritis, psoriasis, and other autoimmune conditions.
-
Patent Coverage Robustness: The broad chemical claims, combined with method protections, create substantial barriers for competitors, although careful navigation is needed due to overlapping IP in cytokine signaling.
-
Opportunities for Collaboration: The patent’s scope suggests potential for licensing or partnership, especially in combination therapies or novel delivery methods.
Conclusion
UK patent GB2474930 delineates a significant innovation in cytokine receptor modulation through small molecules. Its claims protect a broad chemical class and associated therapeutic methods, positioning GlaxoSmithKline favorably within an active and competitive patent landscape. Its strategic value lies in exclusivity over novel compounds capable of targeting immune pathways implicated in various diseases. However, ongoing innovation within cytokine-targeted therapies necessitates vigilance in patent strategies and monitoring of evolving IP assets.
Key Takeaways
-
GB2474930's claims broadly cover small molecules targeting cytokine receptor pathways, emphasizing therapeutic utility in autoimmune diseases.
-
The patent landscape is active with both chemical and method-of-use patents, underscoring the importance of comprehensive IP strategies.
-
Competitive positioning hinges on the breadth of claims, with GSK maintaining significant protection over this therapeutic class.
-
The patent’s scope fosters opportunities for collaboration, licensing, and further innovation in immune modulation.
-
Continuous patent monitoring is critical to safeguard market exclusivity amidst evolving biologics and small-molecule pipelines.
FAQs
1. What specific diseases can GB2474930 potentially treat?
The patent’s claims relate to cytokine receptor modulation, indicating potential efficacy against autoimmune conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
2. How does this patent compare with biologic drugs?
GB2474930 covers small-molecule compounds that offer advantages over biologics, including oral administration, stability, and potentially fewer immunogenicity issues.
3. Can competitors develop similar compounds without infringing the patent?
Given the broad chemical scope of Claim 1, designing structurally distinct but functionally equivalent molecules will be challenging without infringing, unless significantly different chemical scaffolds are employed.
4. What is the scope of patent protection for methods versus compounds?
The patent includes both composition claims (the compounds) and method claims (therapeutic use), providing layered protection against different infringement avenues.
5. Are there any known challenges or litigation related to GB2474930?
As of now, no public information indicates legal disputes concerning this patent, although patent landscape analysis should include ongoing monitoring.
References
- Glaxo Group Limited. GB Patent GB2474930, "Pharmaceutical compositions and methods for cytokine modulation," filed 2014, granted 2018.
- World Intellectual Property Organization (WIPO). WO2017077642, related cytokine receptor inhibitor compounds.
- PatentScope. Patent family and legal status records accessed March 2023.
- European Patent Office (EPO). Similar inventions and patent filings related to cytokine signaling inhibitors.
- Industry Patent Insights. Trends in small-molecule cytokine receptor antagonists and autoimmune disease therapeutics.
